ProCHO® 5 Protein-free CHO Medium Powder kit with HEPES and 0.1% Pluronic® F-68, without L-Glutamine, phenol red, hypoxanthine or thymidine, 500 L (NAO)
ProCHO® 5, protein free CHO medium, with HEPES and 0.1% Pluronic® F-68, without L-Glutamine, phenol red, hypoxanthine or thymidine, 10 L powder kit(NAO)
ProCHO® 5, protein free CHO medium, basal powder, 500 L (NAO)
ProCHO® 5, protein free CHO medium, with HEPES and 0.1% Pluronic® F-68, without L-Glutamine, phenol red, hypoxanthine or thymidine, 50 L powder kit (NAO)
ProCHO® 5, protein free CHO medium, basal powder, 50 L (NAO)
ProCHO® 5 protein free CHO medium, with HEPES and 0.1% Pluronic® F-68, without L-Glutamine, phenol red, hypoxanthine or thymidine, 1 L (NAO)
ProCHO® 4 Protein-free CHO Medium with 0.1% Pluronic® F-68, without L-Glutamin, phenol red, hypoxanthine or thymidine, 1 L.
ProCHO® 4 Protein-free CHO Medium with 0.1% Pluronic® F-68, without L-Glutamin, phenol red, hypoxanthine or thymidine, 1 L
-
Inducible Cas9 T Cells: An Innovative Platform for Allogeneic CAR-T Cell GenerationPoster on inducible Cas9 T Cells
-
Synthego_Lonza_Protocol_Genome Editing of Resting T cellsTechnical Protocol on Genome Editing of Resting T cells for associated White Paper "Genome Editing of Resting T cells"
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.
-
PBMC Based T Cell Proliferation AssayProtocol instructions
-
Instructions for Use – TheraPEAK® T-VIVO® Cell Culture Medium for Gamma Delta (γδ) T CellsInstructions for how to culture gamma delta (γδ) T Cells using TheraPEAK® T-VIVO® Cell Culture Medium
-
Instructions for Use - Dendritic Cell (DC) and T Cell Assay from Matched PBMCsProtocol for DC and T Cell Assay from Matched PBMCs
-
Case Study – Improving the Expansion of Patients' T CellsIn this serum-free media case study, learn how selection of memory T cells can aid in streamlining CAR-T therapies.
-
cGMP Kit T Optimization Protocol - Nucleofector™ 1/2 Device SeriescGMP Cell Line Nucleofector Kit T
-
Synthego-Lonza Genome Editing of Resting T cellsCase Study on Genome Editing of Resting T cells
-
A Novel Chemically Defined Medium Supports Superior Cross-platform T-cell ExpansionThis poster showcases how the chemically defined TheraPEAK® T-VIVO® Medium supports superior T-cell expansion across different platforms.